It is interesting to note that Boston Scientific Corporation (NYSE:BSX) is active and made a solid movement in the last trading day. Now trading with a market value of 36.26B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.
Boston Scientific Corporation (NYSE:BSX) Fundamentals That Matter
It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For BSX, the company currently has 317 million of cash on the books, which is offset by 1.02 billion in current liabilities. The trend over time is important to note. In this case, the company’s debt has been falling. The company also has 18.38 billion in total assets, balanced by 11.15 billion in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.
Boston Scientific Corporation (BSX) saw 117 million in free cash flow last quarter, representing a quarterly net change in cash of 39 million. Perhaps most importantly where cash movements are concerned, the company saw about 185 million in net operating cash flow.
Boston Scientific Corporation (NYSE:BSX) Revenue Growth Potential
As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 2.26 billion in total revenues. That represents a quarterly year/year change in revenues of 0.06 in sequential terms, the BSX saw sales decline by 0.05.
But what about the bottom line? After all, that’s what really matters in the end. Boston Scientific Corporation (BSX) is intriguing when broken down to its core data. The cost of selling goods last quarter was 782 million, yielding a gross basic income of 1.48 billion. For shareholders, given the total diluted outstanding shares of 1.39 billion, this means overall earnings per share of 0.11. Note, this compares with a consensus analyst forecast of 0.31 in earnings per share for its next fiscal quarterly report.
Is Boston Scientific Corporation (NYSE:BSX) Valuation Attractive
Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 1.39 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 18.98. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Boston Scientific Corporation.